Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months

Boston Scientific shares have plummeted over 50% year-to-date due to repeated downward guidance revisions, particularly regarding declining Watchman procedure usage. Despite bearish market sentiment, 27 of 31 analysts maintain buy ratings with a consensus price target of $78 (65% upside), though the article cautions this recovery may be challenging without faster-than-expected growth acceleration.